2023³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-21
±³À°ÀÏÀÚ : 2023-04-21
±³À°Àå¼Ò : ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë
±³À°ÁÖÁ¦ : 2023³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ
´ã´çÀÚ : ±èÈñ¿µ
¿¬¶ôó : 0502-2277-1919
À̸ÞÀÏ : stroke@stroke.or.kr
±³À°Á¾·ù : ½Å°æ¿Ü°ú, ¿µ»óÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú
Âü¼®¿¹»óÀÎ : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í Á¤È¸¿ø(»çÀüµî·Ï 50,000, ¿¬È¸ºñ+»çÀüµî·Ï 120,000¿ø, ÇöÀåµî·Ï 60,000¿ø)/ Á¤È¸¿ø Áß ÀüÀÓÀÇ, °øº¸ÀÇ, ±ºÀÇ°ü(»çÀüµî·Ï 30,000, ¿¬È¸ºñ+»çÀüµî·Ï 100,000¿ø, ÇöÀåµî·Ï 40,000¿ø)/ ÁØȸ¿ø, ÀϹÝȸ¿ø(»çÀüµî·Ï 30,000, ¿¬È¸ºñ+»çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 40,000¿ø)/ ºñȸ¿ø(»çÀüµî·Ï 110,000¿ø, ÇöÀåµî·Ï 120,000¿ø)/ ºñȸ¿ø Áß °£È£»ç(»çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 70,000¿ø)/ Á¤È¸¿ø Áß È¸ºñ¹Ì³³È¸¿ø(»çÀüµî·Ï 130,000¿ø, ÇöÀåµî·Ï 140,000¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 08:50~09:00 Opening Remark ±èÀÀ±Ô(´ëÇѳúÁ¹ÁßÇÐȸ ȸÀå)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 09:00~09:25 Perfusion-weighted imaging ÀÌÁ¤À±(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 09:25~09:50 Genetic testing ÀÌ°ÇÁÖ(°í·ÁÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 09:50~10:15 Long-term cardiac monitoring and PFO ÀåÁØ¿µ(¿ï»êÀÇ´ë ½Å°æ°ú)
Åä·Ð 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 10:15~10:30 Panel discussion ȲÀçÃá, ±èÁØ¿±, ±èÁß±¸(°æºÏÀÇ´ë ½Å°æ°ú, ¼¿ïÀÇ´ë ½Å°æ°ú, Á¦ÁÖÀÇ´ë ½Å°æ°ú)
ÈÞ½Ä 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 10:30~10:50 Break ( )
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 10:50~11:20 Inflammation - the new stroke risk factor and treatment target Peter Kelly(University College Dublin)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 11:20~11:50 Recent advances in moyamoya disease ¹æ¿À¿µ(¼º±Õ°üÀÇ´ë ½Å°æ°ú)
±âŸ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 11:50~12:20 General Assembly ( )
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 12:20~12:50 Long-term antiplatelet therapy for stroke patients ±èÁ¤¹Î(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 12:50~13:20 ROSETTA-Stroke, a Randomized Controlled Trial: Moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target low-density lipoprotein cholesterol goal achievement in patients with recent ischemic stroke È«±Ù½Ä(ÀÎÁ¦ÀÇ´ë ½Å°æ°ú)
ÈÞ½Ä 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 13:20~13:40 Break ( )
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 13:40~14:00 Atrial fibrillation (beyond oral anticoagulation) ¿ÀÀÏ¿µ(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 14:00~14:20 Blood pressure control Kaznori Toyoda(National Cerebral and Cardiovascular Center)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 14:20~14:40 Treatment of DM for CVD prevention ¼Û¼±¿Á(°Çº¸°ø´Ü Àϻ꺴¿ø ½Å°æ°ú)
Åä·Ð 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 14:40~15:00 Panel discussion À̹οì, ±è¿µ¼, °Çö±¸(ÇѸ²ÀÇ´ë ½Å°æ°ú, ¿ø±¤ÀÇ´ë ½Å°æ°ú, ÀüºÏÀÇ´ë ½Å°æ°ú)
ÈÞ½Ä 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 15:00~15:20 Break ( )
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 15:20~15:40 Diagnostic cerebral angiography: How and When, basic anatomy ÀåÀ±°æ(ÀÌÈÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 15:40~16:00 Devices used in neurointervention ±èº¸±Ô(°í·ÁÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 16:00~16:20 Process and procedures in mechanical thrombectomy ¹éÀåÇö(¼º±Õ°üÀÇ´ë ½Å°æ°ú)
Åä·Ð 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 16:20~16:40 Panel discussion °ûµ¿¼®, ¹ÚÇüÁ¾, ½Åµ¿¿ì, ¹ÚÁ¤Áø(µ¿±¹ÀÇ´ë ½Å°æ°ú, °è¸íÀÇ´ë ½Å°æ°ú, ÀÌÈÀÇ´ë ½Å°æ°ú, °Ç±¹ÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 16:40~17:00 Periprocedural complication during reperfusion therapy ¹ÚÁ¤Áø(°Ç±¹ÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 17:00~17:20 Access site complications ȲÁøÈ£(°Ç±¹ÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 17:20~17:40 Blood pressure management after reperfusion therapy Á¤¿äÇÑ(¿¬¼¼ÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 17:40~18:00 Periprocedural antithrombotics ±ÇµÎÇõ(¿µ³²ÀÇ´ë ½Å°æ°ú)
Åä·Ð 04¿ù 21ÀÏ ±×·£µåÇϾæÆ® ¼¿ï ±×·£µåº¼·ë 18:00~19:00 Poster Presentation Professor-Led Poster Tour ( )